Valsartan 160 mg and hydrochlorothiazide 25 mg in subject suffering from arterial hypertension stage 1 or high normal with organ damage - ND
- Conditions
- Arterial Hypertension with organ damage
- Registration Number
- EUCTR2008-000804-10-IT
- Lead Sponsor
- IVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- Male
- Target Recruitment
- Not specified
Inclusion Criteria
-age between 18 and 65 -male -High-normal arterial blood pressure(PA 130-139/85-89 mmHg) -Essential hypertension of grade1
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Endocrine -Unable to practice stress-test by cicloergometer -Mellitus diabet -Anemia (Hb<12,5 g/dl) -Cardiac valvular e/o arhythmic disease
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary end point(s): A better pressure control with significative improvement of organ damage;Main Objective: Percentual of patients that normalize arterial blood pressure;Secondary Objective: Reduction of left ventricular mass; reduction of arterial stiffness
- Secondary Outcome Measures
Name Time Method